SELB News and Press, Selecta Biosciences Inc. From 03/21/23

2023-03-21 09:01:38 ET Investing in penny stocks can be highly rewarding, but it also comes with significant risks. The high-risk, high-reward nature of penny stocks means potential for significant returns. But they can also lose their entire investment if the stock’s price drops...

2023-03-21 06:30:19 ET Selecta Biosciences ( NASDAQ: SELB ) and Swedish Orphan Biovitrum (Sobi) ( OTCPK:BIOVF ) said SEL-212 met the main goals of two phase 3 trials to treat adult patients with chronic refractory gout. Gout is a type of inflammatory arthritis ...

--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II --In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE I and 48% in DISSOLVE II --75% of subjects in the DISSOLVE I extension phase on...

2023-03-16 13:38:32 ET Summary This article covers topics from Christopher Mayer's book "100 Baggers." The book is based on studies by several economists and fund managers who have used strategies to uncover 100X opportunities over time. Many of these discoveries were back-tes...

2023-03-14 06:08:03 ET Summary Selecta Biosciences is a biotech firm working on therapies for rare illnesses. SEL-212, its lead product, helps control uric acid levels in chronic refractory gout patients. SEL-212 controls serum uric acid levels to treat chronic refractory gout by ...

Selecta Biosciences, Inc. (SELB) Q4 2022 Earnings Conference Call March 2, 2023 08:30 ET Company Participants Blaine Davis - Chief Financial Officer Carsten Brunn - President, Chief Executive Officer & Director Peter Traber - Chief Medical Officer Conference ...

Selecta Biosciences press release ( NASDAQ: SELB ): Q4 GAAP EPS of $0.04 beats by $0.11 . Revenue of $16.79M (-43.8% Y/Y) beats by $5.11M . Selecta had $136.2 million in cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2022, as comp...

- Topline data for Phase 3 DISSOLVE I & II clinical trials of SEL-212 in chronic refractory gout remains on track for Q1 2023 - - Continue to enroll patients in ReiMMAgine , the Phase 1/2 clinical trial of SEL-302 for the treatment of methylmalonic acidemia (MMA) -...

Selecta Biosciences ( NASDAQ: SELB ) is scheduled to announce Q4 earnings results on Thursday, March 2nd, before market open. The consensus EPS Estimate is -$0.07 (-170.0% Y/Y) and the consensus Revenue Estimate is $11.68M (-60.9% Y/Y). Over the last 3 months, EPS estimates ha...

WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a co...